EDITORIAL

DOI: http://dx.doi.org/10.15403/jgld-6189

Management of Irritable Bowel Syndrome: The Role of Digital Health Technologies

Arjuna P. De Silva, Krishanni Prabagar, Madunil A. Niriella, Hithanadura J. De Silva

Department of Medicine,
Faculty of Medicine,
University of Kelaniya,
Ragama, Sri Lanka

Address for correspondence:
Prof **Arjuna P. De Silva**,
Department of Medicine,
Faculty of Medicine.
University of Kelaniya, P
O Box 6, Thalagolla Road,
Ragama, GQ 11010, Sri Lanka
apdesilva@kln.ac.lk

Received: 06.03.2025
Accepted: 16.07.2025

INTRODUCTION

Irritable bowel syndrome (IBS) is a prevalent functional gastrointestinal disorder characterized by abdominal pain, bloating, and altered bowel habits without identifiable structural or biochemical abnormalities [1]. It affects approximately 15–20% of the global population, although reported prevalence varies by region and diagnostic criteria used [2, 3]. Beyond symptom burden, IBS significantly impairs patients' quality of life and imposes a considerable financial burden on healthcare systems worldwide [4].

The etiology of IBS is multifactorial, involving complex interactions between altered gastrointestinal motility, visceral hypersensitivity, immune activation, dysbiosis, and gut-brain axis dysregulation [5]. Psychological stressors often exacerbate symptoms, adding to the disorder's complexity [6].

Traditional IBS management includes dietary modifications, pharmacological interventions, and psychological therapies aimed primarily at symptom control [7, 8]. However, treatment efficacy varies greatly, and many patients experience suboptimal relief [8]. This therapeutic gap, along with advancements in digital health, has catalyzed interest in integrating technology into IBS care. In particular, artificial intelligence (AI), wearable biosensors, and mobile health (mHealth) platforms have shown transformative potential.

DIGITAL TECHNOLOGY IN IBS MANAGEMENT

Diagnostic Enhancement

Digital technologies now support more precise diagnostic pathways. Smart capsules, such as CapScan and intestinal bacterial detection systems, can non-invasively assess the gut environment by sampling contents in the small or large intestine and measuring pH, temperature, and gas production [9, 10]. These tools aid in identifying factors such as small intestinal bacterial overgrowth (SIBO), which is frequently associated with IBS symptoms [9].

Furthermore, machine learning algorithms are increasingly utilized to analyze gut microbiota profiles, stool biomarkers, and even patient-reported outcomes. Artificial intelligence based models have demonstrated superior diagnostic accuracy in differentiating IBS subtypes and distinguishing IBS from organic conditions like inflammatory bowel disease (IBD) [11, 12].

Symptom and Lifestyle Monitoring

Wearable devices and mobile apps enable real-time tracking of symptoms, lifestyle factors, and physiological markers. A wide range of wearables, such as smartwatches (e.g., Apple Watch), fitness bands (e.g., Fitbit), rings (e.g., Oura), abdominal patches, chest straps, and smart textiles, can automatically monitor key health metrics, including heart rate, physical activity, and glucose levels [13]. Many of these devices are equipped with biosensors that continuously track heart rate variability (HRV), stress levels, gut motility, and movement [14]. These physiological insights are particularly valuable in managing IBS, where the autonomic nervous system and gut-brain axis play a critical role.

For instance, the E4 Empatica Band measures skin conductance and emotional arousal, serving as an objective measure of stress [15]. Apps like Welltory and Heali collect and interpret biometric data alongside patient-reported symptoms such as abdominal pain, bloating, or altered bowel habits [16].

Self-monitoring tools such as the Monash University FODMAP app help patients identify dietary triggers and follow evidence-based dietary protocols, enhancing adherence and symptom control [17].

Therapeutic Interventions

Digital platforms have also expanded therapeutic options. MHealth apps including Happify, and Headspace offer cognitive behavioral therapy (CBT), mindfulness exercises, and stress management protocols tailored for gastrointestinal distress [18]. These features are particularly valuable for patients whose symptoms are linked to anxiety or depression.

Just-in-time adaptive interventions (JITAIs) delivered through these platforms offer dynamic, responsive therapy. When stress or symptom thresholds are exceeded, patients receive alerts and immediate access to calming interventions [19].

Smartwatches, paired with mobile apps, provide additional insights by enabling continuous biosignal collection. These data inform personalized recommendations and early-warning systems to prevent symptom escalation [20].

Artificial Inteligence Agents Virtual Assistants and Chatbots

Artificial intelligence agents are an emerging class of autonomous, goal-directed systems capable of making decisions, learning from feedback, and taking actions without continuous human input. Unlike traditional AI tools that perform specific tasks, AI agents interact dynamically with users and digital environments, offering personalized support and adaptive management strategies. Examples include advanced virtual assistants and chatbots.

In the management of IBS, AI-driven virtual assistants are becoming increasingly sophisticated. For instance, the EMMA (Emotion-Aware mHealth Agent) chatbot uses smartphone sensor data and patient input to detect psychological states, such as stress, fatigue, or low mood, and delivers tailored micro-interventions, including motivational prompts and breathing exercises [21].

These tools improve adherence and patient autonomy, particularly in remote settings where access to specialists is limited. They also have potential for integration into clinical workflows, enhancing telemedicine consultations with real-time symptom data.

IMPACT ON PATIENT OUTCOME

Digital health technologies have significantly enhanced IBS management by enabling more proactive, personalized, and data-driven care.

Symptom Reduction and Trigger Identification

Wearables and mHealth apps allow patients to identify and avoid symptom triggers such as dietary components, sleep disturbances, or psychological stressors. Real-time feedback empowers patients to make informed behavioral changes that can reduce the frequency and severity of flare-ups [22].

Improved Quality of Life

Digital tools offering stress management, dietary guidance, and behavioral therapy contribute to reductions in anxiety and depression, thereby improving overall quality of life [23]. Psychological comorbidities, which are highly prevalent in IBS, are often addressed more effectively with integrated digital support than with conventional care alone [24].

Increased Treatment Adherence

Digital reminders, visual feedback, and interactive interfaces improve patient engagement and adherence to both pharmacological and non-pharmacological treatments [25]. This is particularly evident among younger populations, who are more comfortable navigating digital platforms.

Reduced Healthcare Utilization

By facilitating self-management and early intervention, digital technologies help reduce emergency visits, unnecessary diagnostic testing, and reliance on specialist consultations. This, in turn, eases the burden on healthcare systems and lowers overall treatment costs [26].

CHALLENGES AND BARRIERS

Despite promising outcomes, several challenges hinder the widespread implementation of digital health technologies in IBS care.

Data Accuracy and Interpretation

Wearables and mobile apps can generate false positives or inconsistent data due to motion artifacts, improper use, or poor user compliance. Without clinical oversight, this may lead to misinterpretation and misguided interventions [27].

Data Privacy and Security

The use of personal health information (PHI) in digital applications raises concerns about data breaches, consent, and third-party access. Robust cybersecurity protocols and clear data governance policies are essential to protect patient confidentiality and build trust in these systems [28].

Accessibility and the Digital Divide

Not all patients have equal access to smartphones, wearables, or reliable internet. Elderly individuals, economically disadvantaged groups, and those in rural areas may face barriers to adopting digital solutions, exacerbating health inequities [29].

Quality Control in Artificial Intelligence based Advice

Some patients rely on general-purpose AI tools for dietary or therapeutic advice, which may not be evidence-based or tailored to individual needs. This can result in misinformation and, in some cases, harm. Regulation and validation of clinical AI tools are urgently needed [30].

FUTURE PROSPECTS

As digital health technologies evolve, their potential in IBS management is expected to expand dramatically.

Early Diagnosis via Artificial Intelligence

Emerging research from institutions like Cambridge University demonstrates the potential of AI to predict IBS risk by analyzing gut microbiome data before clinical symptoms manifest [31]. Such predictive models could shift the paradigm from reactive treatment to early intervention and prevention.

Artificial Intelligence Integrated Clinical Decision Support

Platforms that integrate electronic medical records with wearable and patient-reported data will soon provide clinicians with real-time, AI-enhanced decision support. Initiatives such as the Google–Mayo Clinic partnership exemplify this integration, aiming to optimize individualized care plans [32].

Virtual Reality and Immersive Therapies

Virtual reality (VR)-based cognitive therapies are under investigation as novel interventions for gut-brain disorders. Early trials suggest VR can enhance outcomes in patients unresponsive to conventional therapies by reducing visceral hypersensitivity and stress [33].

Adaptive, Precision-Guided Protocols

Reinforcement learning algorithms will eventually power adaptive treatment regimens that evolve in response to patient outcomes, eliminating the guesswork inherent in current IBS management. This level of personalization has the potential to significantly improve long-term disease control [34].

CONCLUSIONS

The convergence of AI, wearable technology, and mobile health platforms is revolutionizing the management of IBS and related functional gastrointestinal disorders. These tools facilitate early diagnosis, continuous symptom monitoring, and evidence-based interventions tailored to individual patient profiles.

Despite challenges related to data accuracy, privacy, and accessibility, the momentum behind digital health innovation is undeniable. With continued interdisciplinary collaboration and rigorous clinical validation, digital technologies are poised to transform IBS care—from reactive symptom relief to proactive, precision-guided management.

Conflicts of interest: None to declare.

Author's contributions: A.P.D.S conceptualised the paper. A.P.D.S and K.P collected and analysed the evidence and drafted the manuscript A.P.D.S, K.P, M.A.N and H.J.D.S were substantially involved in revising the manuscript. All authors checked the final manuscript, approved the final version to be published and agreed to be accountable for all aspects of the work..

REFERENCES

1. Holtmann G, Shah A, Morrison M. Pathophysiology of Functional Gastrointestinal Disorders: A Holistic Overview. Dig Dis 2018;35 Suppl. 1:5–13. doi:10.1159/000485409
2. Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol 2012;10:712–721. doi:10.1016/j.cgh.2012.02.029
3. Oka P, Parr H, Barberio B, Black CJ, Savarino EV, Ford AC. Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2020;5:908–917. doi:10.1016/S2468-1253(20)30217-X
4. Canavan C, West J, Card T. The epidemiology of irritable bowel syndrome. Clin Epidemiol 2014;6:71–80. doi:10.2147/CLEP.S40245
5. Enck P, Aziz Q, Barbara G, et al. Irritable bowel syndrome. Nat Rev Dis Primers 2016;2:16014. doi:10.1038/nrdp.2016.14
6. Chang L. The role of stress on physiologic responses and clinical symptoms in irritable bowel syndrome. Gastroenterology 2011;140:761–765. doi:10.1053/j.gastro.2011.01.032
7. Moayyedi P, Ford AC, Talley NJ, et al. The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. Gut 2010;59:325–332. doi:10.1136/gut.2008.167270
8. Fikree A, Byrne P. Management of functional gastrointestinal disorders. Clin Med 2021;21:44-52. doi:10.7861/clinmed.2020-0980
9. Quigley EMM. Small intestinal bacterial overgrowth: what it is and what it is not. Curr Opin Gastroenterol 2020;36:141–146. doi:10.1097/MOG.0000000000000040
10. Rehan M, Al-Bahadly I, Thomas DG, Young W, Cheng LK, Avci E. Smart capsules for sensing and sampling the gut: status, challenges and prospects. Gut. 2024;73:186. doi:10.1136/gutjnl-2023-329614
11. Tap J, Derrien M, Törnblom H, et al. Identification of an intestinal microbiota signature associated with severity of IBS. Gastroenterology 2017;152:111–123.e8. doi:10.1053/j.gastro.2016.09.049
12. Vulpoi RA, Luca M, Ciobanu A, Olteanu A, Bărboi O, Iov D-E, et al. The potential use of artificial intelligence in irritable bowel syndrome management. Diagnostics (Basel). 2023;13:3336. doi:10.3390/diagnostics13213336
13. Chong KP, Woo BK. Emerging wearable technology applications in gastroenterology: A review of the literature. World J Gastroenterol 2021;27:1149-1160. doi:10.3748/wjg.v27.i12.1149
14. Gedam S, Paul S. A review on mental stress detection using wearable sensors and machine learning techniques. IEEE Access. 2021;9:84045. doi:10.1109/ACCESS.2021.3085502
15. Empatica. Empatica E4: Research Publications. Available from: https://www.empatica.com/research/publications
16. Akbarian P, Asadi F, Sabahi A. Developing mobile health applications for inflammatory bowel disease: A systematic review of features and technologies. Middle East J Dig Dis 2024;16:211-220. doi:10.34172/mejdd.2024.394
17. Monash University. Monash University Low FODMAP Diet App wins Gold in Edison Awards. Monash University; 2020 Mar 26. Available from: https://www.monash.edu/medicine/news/latest/2020-articles/monash-university-low-fodmap-diet-app-wins-gold-in-edison-awards
18. Sano A, Phillips AJ, Yu AZ, et al. Recognizing academic performance, sleep quality, stress level, and mental health using personality traits, wearable sensors and mobile phones. Int Conf Wearable Implant Body Sens Netw 2015:2015:10.1109/BSN.2015.7299420. doi:10.1109/BSN.2015.7299420
19. Nahum-Shani I, Smith SN, Spring BJ, et al. Just-in-time adaptive interventions (JITAIs) in mobile health: Key Components and Design Principles for Ongoing Health Behavior Support. Ann Behav Med 2018;52:446–462. doi:10.1007/s12160-016-9830-8
20. Seshadri DR, Li RT, Voos JE, et al. Wearable Sensors for Monitoring the Physiological and Biochemical Profile of the Athlete. NPJ Digit Med 2019;2:72. doi:10.1038/s41746-019-0150-9
21. Ghandeharioun A, McDuff D, Czerwinski M, Rowan K. EMMA: An Emotion-Aware Wellbeing Chatbot. In: Proceedings of the 2019 8th International Conference on Affective Computing and Intelligent Interaction (ACII); 2019 Sep; Cambridge, United Kingdom. IEEE; 2019:1–7. doi:10.1109/ACII.2019.8925455

22. Moreno-Ligero M, Moral-Munoz JA, Salazar A, Failde I. mHealth intervention for improving pain, quality of life, and functional disability in patients with chronic pain: systematic review. JMIR Mhealth Uhealth 2023;11:e40844. doi:10.2196/40844
23. Pathipati MP, Scott LL, Griser AC, Staller K. Real-world outcomes for a digital prescription mobile application for adults with irritable bowel syndrome. Neurogastroenterol Motil 2024;36:e14811. doi:10.1111/nmo.14811
24. Warner MM, Soliman OM, Crichton M, Marshall S, Staudacher HM, Kelly JT. Systematic Review: Integrated Models of Care for Managing Irritable Bowel Syndrome. Neurogastroenterol Motil 2025;37:e14989. doi:10.1111/nmo.14989
25. Badawy SM, Barrera L, Sinno MG, Kaviany S, O'Dwyer LC, Kuhns LM. Text Messaging and Mobile Phone Apps as Interventions to Improve Adherence in Adolescents with Chronic Health Conditions: A Systematic Review. JMIR Mhealth Uhealth 2017;5(5):e66. doi:10.2196/mhealth.7798
26. Zhang F, Xiang W, Li CY, Li SC. Economic burden of IBS in China. World J Gastroenterol 2016;22:10450–10460. doi:10.3748/wjg.v22.i47.10450
27. Piwek L, Ellis DA, Andrews S, Joinson A. The rise of consumer health wearables: promises and barriers. PLoS Med 2016;13:e1001953. doi:10.1371/journal.pmed.1001953
28. Luxton DD, Kayl RA, Mishkind MC. mHealth data security: the need for HIPAA-compliant standardization. Telemed J E Health 2012;18:284–288. doi:10.1089/tmj.2011.0180
29. Anderson M, Perrin A. Technology use among seniors. Pew Research Center 2017 May 17. Available from: https://www.pewresearch.org/internet/2017/05/17/technology-use-among-seniors/
30. Heaven WD. AI is giving doctors better bedside manner. But it could also be dangerous. MIT Technology Review 2021 Mar 3. Available from: https://www.technologyreview.com/2021/03/03/1020600/ai-doctors-better-bedside-manner/
31. Liu Y, Ritchie SC, Teo SM, et al. Integration of polygenic and gut metagenomic risk prediction for common diseases. Nat Aging 2024;4:584–594. doi:10.1038/s43587-024-00590-7
32. Mayo Clinic selects Google as strategic partner for health care innovation, cloud computing. Mayo Clinic News Network 2019 Sep 10. Available from: https://newsnetwork.mayoclinic.org/discussion/mayo-clinic-selects-google-as-strategic-partner-for-health-care-innovation-cloud-computing/
33. Suchak KK, Almario CV, Liran O, Chernoff R, Spiegel BMR. The Role of Virtual Reality in the Management of Irritable Bowel Syndrome. Curr Gastroenterol Rep 2024;26:294-303. doi:10.1007/s11894-024-00940-w
34. Yu KH, Beam AL, Kohane IS. Artificial intelligence in healthcare. Nat Biomed Eng 2018;2:719–731. doi:10.1038/s41551-018-0305-z